uniQure Pharma - רווח נקי למניה אחת בשנים עשר החודשים האחרונים QURE

The YoY net income per share growth for uniQure N.V. (QURE) over the last 12 months demonstrates a current level of approximately 18.90. This trend is supported by the implementation of energy-saving technologies in laboratories and strict environmental controls. Matt Kapusta's expert management relies on in-house capacities and partnerships. Business stability is ensured through diversification via royalties and the development of independent therapy programs for neurological pathologies.
פילוחי מדדים פיננסיים ומדדי שוק עבור uniQure N.V. (QURE)

This indicator measures the rate of change in earnings per share (EPS) over a rolling year, reflecting the dynamics of shareholder value generation relative to previous periods. By analyzing the annual EPS growth rate over the last 12 months, investors assess the efficiency of uniQure N.V. (QURE) capital expenditures in high-cost gene therapy development and the ability of innovative treatments for rare diseases to translate into tangible financial results.